GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » EPS (Diluted)

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) EPS (Diluted) : $0.01 (TTM As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories EPS (Diluted)?

Rapid Therapeutic Science Laboratories's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01.

Rapid Therapeutic Science Laboratories's EPS (Basic) for the three months ended in Jun. 2023 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01.

Rapid Therapeutic Science Laboratories's EPS without NRI for the three months ended in Jun. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Rapid Therapeutic Science Laboratories EPS (Diluted) Historical Data

The historical data trend for Rapid Therapeutic Science Laboratories's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Therapeutic Science Laboratories EPS (Diluted) Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.00 -7.25 -0.25 -0.38 -0.23

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.03 0.01 0.02 0.01

Competitive Comparison of Rapid Therapeutic Science Laboratories's EPS (Diluted)

For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Therapeutic Science Laboratories's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's PE Ratio distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's PE Ratio falls into.



Rapid Therapeutic Science Laboratories EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Rapid Therapeutic Science Laboratories's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.795-0)/7.747
=-0.23

Rapid Therapeutic Science Laboratories's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.046-0)/8.318
=0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Rapid Therapeutic Science Laboratories EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201
Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.
Executives
Henry Anthony Punzi director 1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin director 639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier 10 percent owner 7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr. director, 10 percent owner, officer: President and CEO 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson director, officer: Chief Operating Officer 2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc. 10 percent owner 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler director, officer: CFO 2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond director, officer: CFO 28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson director, officer: CEO and President 5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130